THIRD-PARTY REVIEW PROVISIONS "CRITICAL" TO FDA REFORM, REP. GREENWOOD SAYS; HOUSE COMMERCE COMMITTEE PLANS TO BEGIN HEARINGS MAY 1, FINISH MARK-UP BY MID-JUNE
Executive Summary
A House-Senate conference agreement on FDA reform has become "a lot easier to imagine" following the inclusion in the Senate bill (S 1477) of an amendment creating a three-year pilot for third-party review of all medical devices, Rep. Greenwood (R-Penn.) asserted during remarks before the American Enterprise Institute in Washington, D.C. on April 16.Register for our free email digests: